News
ICAD
1.600
+1.59%
0.025
Weekly Report: what happened at ICAD last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ICAD last week (0311-0315)?
Weekly Report · 03/18 12:16
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Analysts have issued new ratings on iCAD, Mustang Bio and Cerus. BTIG maintained a Buy rating on the Healthcare sector with a price target of $3.00 for iCad. In a report released yesterday, BTIG also maintained a Hold rating on Cerus and a Buy on Mustang Bio.
TipRanks · 03/13 10:10
icad: Q4 Earnings Insights
Icad reported its Q4 earnings of $-0.02 on March 12. The company's revenue was down $1.75 million from the same period last year. Icad beat estimates by 60.0%. The company is expected to announce its earnings Tuesday.
Benzinga · 03/12 20:10
iCAD Non-GAAP EPS of -$0.02 beats by $0.03, revenue of $4.74M beats by $0.46M
Seeking Alpha · 03/12 20:02
BRIEF-iCAD, Inc. Q4 Gross Profit USD 4.3 Million
Reuters · 03/12 20:01
Press Release: iCAD Announces Fiscal Fourth -4-
Starting in the third quarter of 2023, the Company began reporting Annual Recurring Revenue ("ARR") with each quarterly earnings announcement. The Company excludes litigation costs from its non-GAAP measures because it does not have a direct correlation to future business operations. The Company's annualized subscription revenue is not a replacement for GAAP revenue.
Dow Jones · 03/12 20:01
Press Release: iCAD Announces Fiscal Fourth -3-
Comprehensive net loss for the three months ended December 31, 2017 was $1,362. The company reported a net loss of $1.2 million. The Company's net loss per share was $0.08 for the quarter. For the year, the company lost $2.1 million. The company's total losses for the year were $3.1 billion.
Dow Jones · 03/12 20:01
Press Release: iCAD Announces Fiscal Fourth -2-
Certain statements contained in this News Release constitute "forward-looking statements" iCAD, Inc. Faces a number of known and unknown risks, uncertainties, and other factors. The Company's actual results, performance, or achievements may be materially different from those expressed or implied by such statements.
Dow Jones · 03/12 20:01
*ICAD 4Q EPS 5c >ICAD
Dow Jones · 03/12 20:01
*ICAD 4Q Rev $4.74M >ICAD
Dow Jones · 03/12 20:01
Craig-Hallum Gives a Buy Rating to iCAD (ICAD)
TipRanks · 03/12 12:56
Earnings Scheduled For March 12, 2024
Aurora Mobile is likely to report earnings for its fourth quarter. Manchester United is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million. Kohl's is expected to report before the bell and after the bell. Other companies reporting before and after bell include Aurora Mobile, Enfusion and Hagerty.
Benzinga · 03/12 09:35
Notable earnings after Tuesday's close
Seeking Alpha · 03/11 21:35
iCAD Q4 2023 Earnings Preview
Seeking Alpha · 03/11 21:35
Weekly Report: what happened at ICAD last week (0304-0308)?
Weekly Report · 03/11 12:11
Weekly Report: what happened at ICAD last week (0226-0301)?
Weekly Report · 03/04 12:15
ICAD stock jumps 11% ahead of medical meeting presentations
Seeking Alpha · 02/28 15:38
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
ICAD, Inc. Will highlight scientific presentations at the European Congress of Radiology annual meeting in Vienna, Austria, in 2024. The Company is a global leader in clinically proven AI-powered solutions to detect cancer earlier and improve patient outcomes. ICAD will highlight a new release for its ProFound Detection solution.
Barchart · 02/28 07:05
*ICAD Expands Bd of Directors With the Appointment of Dr. Hedvig Hricak, MD, PhD
Dow Jones · 02/27 14:05
More
Webull provides a variety of real-time ICAD stock news. You can receive the latest news about Icad Inc through multiple platforms. This information may help you make smarter investment decisions.
About ICAD
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.